Orchestra BioMed (OBIO) director David Hochman buys 10,000 shares

Rhea-AI Filing Summary

Orchestra BioMed Holdings director and officer David P. Hochman bought 10,000 shares of Common Stock in an open-market purchase at a weighted average price of $4.29 per share. After this transaction, he directly owns 1,086,467 shares, with additional indirect holdings reported through several family trusts.

Insider Trade Summary

Net Buyer: 10,000 shares ($42,900)

Net Buy 6 txns

Insider Hochman David P

Role See Remarks

Bought 10,000 shs ($43K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share ("Common Stock")	10,000	$4.29	$43K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock, par value $0.0001 per share ("Common Stock") — 1,086,467 shares (Direct); Common Stock — 439,482 shares (Indirect, By the DPH 2008 Trust)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hochman David P

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	03/13/2026		P		10,000	A	$4.29(1)	1,086,467	D
Common Stock								439,482	I	By the DPH 2008 Trust
Common Stock								2,000	I	By the Solomon Ascher Hochman 2019 Trust
Common Stock								2,000	I	By the Hannah Hochman 2019 Trust
Common Stock								2,000	I	By the Judah Herman Hochman 2019 Trust
Common Stock								3,140	I	By the NSH 2008 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.28 to $4.30. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Chief Executive Officer and Chairperson

	/s/ Andrew Taylor, Attorney-in-Fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OBIO director David Hochman report?

David P. Hochman reported buying 10,000 shares of Orchestra BioMed Common Stock in an open-market transaction. The weighted average purchase price was $4.29 per share, based on multiple trades between $4.28 and $4.30 on the transaction date.

At what price were the Orchestra BioMed (OBIO) shares purchased?

The reported purchase price was a weighted average of $4.29 per share. The filing notes the shares were acquired in multiple trades, with individual prices ranging from $4.28 to $4.30 per share on the same day.

How many OBIO shares does David Hochman hold directly after the transaction?

Following the reported purchase, David P. Hochman directly holds 1,086,467 shares of Orchestra BioMed Common Stock. This figure reflects his direct ownership position immediately after acquiring the additional 10,000 shares in the open-market transaction described.

Does David Hochman have indirect Orchestra BioMed shareholdings?

Yes. The filing shows indirect holdings through several trusts, including 439,482 shares held by the DPH 2008 Trust and smaller positions of 2,000 or 3,140 shares held by various 2019 and family trusts associated with members of the Hochman family.

What does transaction code P mean in this OBIO Form 4 filing?

Transaction code P indicates an open-market or private purchase of securities. In this case, it confirms that David P. Hochman bought Orchestra BioMed Common Stock rather than selling or transferring shares for tax, gifting, or restructuring purposes.